Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 509

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 509
---
555,554 | ​ | ​ | ​ | ​       | ​ | 16,666,666 | ​ | ​ | ​ | ​       | ​ | 82,546,600 | ​ | ​ | ​ | ​       | ​ | 16,666,666 | ​ | ​ |
| Basic and diluted net loss per member unit          | ​ | ​ | ​                                       | $ |      -0.02 | ​ | ​ | ​ | ​       | $ |      -0.10 | ​ | ​ | ​ | ​       | $ |      -0.03 | ​ | ​ | ​ | ​       | $ |      -0.13 | ​ | ​ |

Recently Issued Accounting Pronouncements In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . The standard requires entities to disclose additional categories about federal, state and foreign income taxes in the effective tax rate reconciliation as well as provide

F-60

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO CONDENSED FINANCIAL STATEMENTS

#### SEPTEMBER 30, 2024
<div align='center'>**(Unaudited)**</div>

annual income taxes paid disaggregated by federal, state and foreign taxes. The standard is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating the impact of adopting this standard on its financial statements and related disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The standard improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and information used to assess segment performance. All disclosure requirements of the update are required for entities with a single reportable segment. The standard is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and requires retrospective application to all prior periods presented in the unaudited condensed financial statements. The Company is evaluating the impact of adopting this standard on its financial statements and related disclosures.

#### Note 3. License Agreements
Metavagen License

In December 2022, the Company entered into a Subscription Agreement In Kind with Metavagen LLC (“Metavagen